| Literature DB >> 29482600 |
Animut Alebel1, Fasil Wagnew2, Cheru Tesema2, Getiye Dejenu Kibret2, Pammla Petrucka3,4, Setegn Eshite5.
Abstract
BACKGROUND: The relationship between undernutrition and HIV is bidirectional, ultimately contributing to quality of life and survival of affected individuals. Ethiopia is a sub-Saharan nation influenced by both undernutrition and HIV. In Ethiopia, although individuals are often dually impacted, the effect of undernutrition on the survival of HIV positive children on anti-retroviral therapy (ART) has not been well investigated. Therefore, this study assessed the effect of undernutrition on survival rates of HIV positive children on ART in Amhara Regional State of Ethiopia.Entities:
Keywords: Anti-retroviral therapy (ART); Children; HIV; Mortality; Undernutrition
Mesh:
Substances:
Year: 2018 PMID: 29482600 PMCID: PMC5828475 DOI: 10.1186/s13052-018-0472-2
Source DB: PubMed Journal: Ital J Pediatr ISSN: 1720-8424 Impact factor: 2.638
Baseline socio-demographic characteristics of HIV infected children on ART in Amhara Regional State referral hospitals, Ethiopia, January 1st, 2012 – February 28th, 2017
| Variables | Frequency (N) | Percentage (%) |
|---|---|---|
| Sex | ||
| Male | 180 | 46.1 |
| Female | 210 | 53.9 |
| Age | ||
| < 1 year | 11 | 2.8 |
| 1-5 years | 116 | 29.7 |
| 5-15 years | 263 | 67.4 |
| Residence | ||
| Urban | 333 | 85.4 |
| Rural | 57 | 14.6 |
| Marital status of caregiver (379) | ||
| Single | 44 | 11.6 |
| Married | 191 | 50.4 |
| Divorced | 54 | 14..3 |
| Widowed | 90 | 23.7 |
| Parental status | ||
| Both alive | 223 | 57.2 |
| Father dead | 73 | 18.7 |
| Mother dead | 37 | 9.5 |
| Both dead | 57 | 14.6 |
| Caregiver of the child | ||
| Parent | 324 | 83.0 |
| Sister/Brother | 17 | 4.4 |
| Uncle/aunt | 9 | 2.3 |
| Grandparent | 25 | 6.4 |
| Others | 15 | 3.9 |
Baseline clinical and immunological profile of HIV positive children on ART in Amhara Regional State referral hospitals, Ethiopia from the 1st of January, 2012 – the 28th February, 2017
| Variables | Frequency (N) | Percentage (%) |
|---|---|---|
| OI at baseline | ||
| Yes | 182 | 53.3 |
| No | 208 | 46.7 |
| Functional status (age ≥5 year) ( | ||
| Working | 150 | 57.3 |
| Ambulatory | 105 | 40.1 |
| Bedridden | 7 | 2.7 |
| Developmental History (age < 5 years) ( | ||
| Appropriate | 97 | 75.8 |
| Delayed | 24 | 17.8 |
| Regressive | 7 | 5.5 |
| WHO clinical stage | ||
| Stage I and II | 229 | 58.8 |
| Stage III and IV | 161 | 41.2 |
| Past TB test before ART | ||
| Not determined | 310 | 79.5 |
| Negative | 37 | 9.5 |
| Positive | 43 | 11.0 |
| Past TB treatment | ||
| No treatment | 346 | 88.7 |
| 2SRHZ/4RH | 30 | 7.7 |
| 2HRZES/4HRE | 3 | 0.8 |
| HRZE/4RH | 11 | 2.8 |
| CD4 count or percent | ||
| Below the threshold | 273 | 70.0 |
| Above the threshold | 117 | 30.0 |
| Hemoglobin level | ||
| < 10 g/dl | 47 | 12.0 |
| ≥10 g/dl | 343 | 88.0 |
| ART eligibility criteria | ||
| Immunologic/ CD4 | 107 | 27.9 |
| WHO clinical stage | 47 | 12.0 |
| Both clinical and immunologic | 152 | 39.0 |
| Without criteria | 84 | 21.5 |
| Type of Regimen during follow up | ||
| 4a = d4t-3TC-NVP | 48 | 12.3 |
| 4b = d4t-3TC-EFV | 22 | 5.6 |
| 4c = AZT-3TC-NVP | 149 | 38.2 |
| 4d = AZT-3TC-EFV | 78 | 20.0 |
| 1e = TDF-3TC-EFV | 35 | 9.0 |
| 1 h = ABC-3TC-NVP | 10 | 2.6 |
| 1 g = ABC-3TC-EFV | 13 | 3.3 |
| 2nd line | 9 | 2.3 |
| Others | 26 | 6.7 |
| OI during follow-up | ||
| Yes | 107 | 27.4 |
| No | 283 | 72.6 |
| Cotrimoxazole preventive therapy | ||
| Yes | 233 | 59.7 |
| No | 157 | 40.3 |
| Regimen change during follow-up | ||
| Yes | 118 | 30.3 |
| No | 272 | 69.7 |
| Regimen stopped during follow-up | ||
| Yes | 18 | 4.6 |
| No | 372 | 95.4 |
| ART adherence in the 1st 3 months | ||
| Good /fair | 495 | 92.2 |
| Poor | 42 | 7.8 |
Baseline nutritional status of HIV positive children on ART in Amhara Regional State referral hospitals, Ethiopia from the 1st of January, 2012 – the 28th February, 2017
| Variables | Frequency (N) | Percent (%) |
|---|---|---|
| Underweight | ||
| Normal | 252 | 64.6 |
| Moderate (WAZ < − 2) | 79 | 20.3 |
| Severe (WAZ < −3) | 59 | 15.1 |
| Stunting | ||
| Normal | 266 | 68.2 |
| Moderate (HAZ < −2) | 47 | 12.0 |
| Severe (HAZ < − 3) | 77 | 19.7 |
| Wasting | ||
| Normal | 287 | 73.6 |
| Moderate (WHZ or BAZ < − 2) | 49 | 12.6 |
| Severe (WHZ or BAZ < −3) | 54 | 13.9 |
Fig. 1The Kaplan-Meier survival curves to compare survival time of HIV positive children on ART with different categories of nutritional status in Amhara Regional State referral hospitals, Northwest Ethiopia from January 1st, 2012- February 28th, 2017
Fig. 2The Kaplan-Meier survival curves to compare survival time of HIV positive children on ART with different categories of hemoglobin level in Amhara Regional State referral hospitals, Northwest Ethiopia from January 1st, 2012- February 28th, 2017
Fig. 3The Kaplan-Meier survival curves to compare survival time of HIV positive children on ART with different categories of WHO clinical staging in Amhara Regional State referral hospitals, Northwest Ethiopia from January 1st- February 28th, 2017
Fig. 4The Kaplan-Meier survival curves to compare survival time of HIV positive children on ART with different categories of CD4 count or percent in Amhara Regional State referral hospitals, Northwest Ethiopia from January 1st- February 28th, 2017
The bivariable and multivariable Cox regression analysis of predictors of mortality among HIV positive children on ART in Amhara Regional State referral hospitals, Ethiopia from January 1st, 2012 - February 28th, 2017
| Variables | Survival status | CHR (95%CI) | AHR (95%CI) | |
|---|---|---|---|---|
| Sex | ||||
| Male | 23 | 154 | 2.5 (1.3, 5.0) | 1.3 (0.6, 3.0) |
| Female | 15 | 198 | 1 | 1 |
| Age | ||||
| < 1yer | 3 | 8 | 4.9 (1.4, 17.0) | 2.5 (0.6, 9.9) |
| 1-5 years | 17 | 99 | 2.2(1.1, 4.3) | 1.7(0.7, 3.7) |
| 5-15 years | 18 | 245 | 1 | 1 |
| Residence | ||||
| Urban | 35 | 298 | 1 | 1 |
| Rural | 3 | 54 | 0.6(0.2, 2.0) | 0.5(0.1, 1.7) |
| OI at baseline | ||||
| Yes | 30 | 152 | 4.3 (2.0,9.0) | 1.9 (0.8, 4.5) |
| No | 8 | 200 | 1 | 1 |
| WHO clinical staging | ||||
| Stage I and II | 8 | 221 | 1 | 1 |
| Stage III and IV | 30 | 131 | 5.6 (2.6, 12.3) | 2.6 (1.1, 6.6)** |
| CD4 count or percent | ||||
| Below the threshold | 33 | 2410 | 3.2 (1.2, 8.2) | 5.2 (1.9, 14.1)** |
| Above the threshold | 5 | 112 | 1 | 1 |
| Hemoglobin level | ||||
| < 10 g/dl | 15 | 32 | 6.2 (3.2, 11.9) | 3.2 (1.4, 7.4)** |
| ≥ 10 g/dl | 23 | 320 | 1 | 1 |
| Underweight | ||||
| Normal | 10 | 242 | 1 | |
| Moderate (WAZ < − 2 | 13 | 66 | 4.2 (1.8, 9.6) | 2.4 (0.9,6.4) |
| Severely (WAZ < −3) | 15 | 44 | 6.8 (3.01, 15.2) | 1.3 (0.5, 3.6) |
| Stunting | ||||
| Normal | 12 | 254 | 1 | 1 |
| Moderate (HAZ < −2) | 8 | 39 | 3.9 (1.6, 9.7) | 2.3 (0.9, 6.29) |
| Severe (HAZ < −3) | 18 | 59 | 6.1 (2.9, 12.9) | 3.9 (1.7, 9.4)** |
| Wasting | ||||
| Normal | 18 | 269 | 1 | 1 |
| Moderate (WHZ or BAZ < −2) | 5 | 44 | 1.5 (0.5, 4.0) | 1.2 (0.4, 3.6) |
| Severe (WHZ or BAZ < −3) | 15 | 39 | 4.5 (2.2,9.0) | 3.0 (1.3, 6.9)** |
**Significant predictors in the multivariable analysis